CN113730592A - 一种鸭坦布苏病毒病活疫苗冻干保护剂及制备方法和应用 - Google Patents
一种鸭坦布苏病毒病活疫苗冻干保护剂及制备方法和应用 Download PDFInfo
- Publication number
- CN113730592A CN113730592A CN202111033109.1A CN202111033109A CN113730592A CN 113730592 A CN113730592 A CN 113730592A CN 202111033109 A CN202111033109 A CN 202111033109A CN 113730592 A CN113730592 A CN 113730592A
- Authority
- CN
- China
- Prior art keywords
- duck tembusu
- tembusu virus
- protective agent
- freeze
- live vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 83
- 239000003223 protective agent Substances 0.000 title claims abstract description 58
- 241000686770 Duck Tembusu virus Species 0.000 title claims abstract description 50
- 238000004108 freeze drying Methods 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims description 11
- 201000010099 disease Diseases 0.000 claims abstract description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 14
- 108010010803 Gelatin Proteins 0.000 claims abstract description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 13
- 229930006000 Sucrose Natural products 0.000 claims abstract description 13
- 229920000159 gelatin Polymers 0.000 claims abstract description 13
- 239000008273 gelatin Substances 0.000 claims abstract description 13
- 235000019322 gelatine Nutrition 0.000 claims abstract description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 13
- 239000005720 sucrose Substances 0.000 claims abstract description 11
- 239000008215 water for injection Substances 0.000 claims abstract description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000008101 lactose Substances 0.000 claims abstract description 10
- 239000000600 sorbitol Substances 0.000 claims abstract description 10
- 239000012137 tryptone Substances 0.000 claims abstract description 10
- 239000005018 casein Substances 0.000 claims abstract description 8
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000021240 caseins Nutrition 0.000 claims abstract description 8
- 229920001503 Glucan Polymers 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000011550 stock solution Substances 0.000 claims abstract description 5
- 238000009777 vacuum freeze-drying Methods 0.000 claims abstract description 5
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 3
- -1 polypeptone Substances 0.000 claims abstract description 3
- 239000012153 distilled water Substances 0.000 claims description 10
- 239000011521 glass Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 108010076119 Caseins Proteins 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000008236 heating water Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 3
- 108010079058 casein hydrolysate Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002577 cryoprotective agent Substances 0.000 claims 3
- 241000700605 Viruses Species 0.000 abstract description 20
- 238000000034 method Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 230000000704 physical effect Effects 0.000 abstract description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 210000003746 feather Anatomy 0.000 description 12
- 241000272517 Anseriformes Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229960004793 sucrose Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 238000007865 diluting Methods 0.000 description 6
- 241000272525 Anas platyrhynchos Species 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 241000907504 Tembusu virus Species 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 231100000645 Reed–Muench method Toxicity 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111033109.1A CN113730592B (zh) | 2021-09-03 | 2021-09-03 | 一种鸭坦布苏病毒病活疫苗冻干保护剂及制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111033109.1A CN113730592B (zh) | 2021-09-03 | 2021-09-03 | 一种鸭坦布苏病毒病活疫苗冻干保护剂及制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113730592A true CN113730592A (zh) | 2021-12-03 |
CN113730592B CN113730592B (zh) | 2023-12-19 |
Family
ID=78735487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111033109.1A Active CN113730592B (zh) | 2021-09-03 | 2021-09-03 | 一种鸭坦布苏病毒病活疫苗冻干保护剂及制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113730592B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116440282A (zh) * | 2023-05-09 | 2023-07-18 | 中海生物制药(泰州)有限公司 | 一种鸡传染性支气管炎活疫苗冻干保护剂及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105274064A (zh) * | 2015-11-30 | 2016-01-27 | 齐鲁动物保健品有限公司 | 一种鸭坦布苏病毒弱毒疫苗株及其应用 |
CN107281481A (zh) * | 2017-08-02 | 2017-10-24 | 华派生物工程集团有限公司 | 一种伪狂犬活疫苗耐热冻干保护剂、制备方法和冻干疫苗及制备方法 |
CN108815517A (zh) * | 2018-07-13 | 2018-11-16 | 广东永顺生物制药股份有限公司 | 一种鸭瘟活疫苗及其制备方法 |
CN108992674A (zh) * | 2018-07-13 | 2018-12-14 | 广东永顺生物制药股份有限公司 | 一种耐热保护剂及其应用 |
EP3493839A1 (en) * | 2016-08-03 | 2019-06-12 | Takeda Vaccines, Inc. | Compositions and methods for stabilizing flaviviruses with improved formulations |
-
2021
- 2021-09-03 CN CN202111033109.1A patent/CN113730592B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105274064A (zh) * | 2015-11-30 | 2016-01-27 | 齐鲁动物保健品有限公司 | 一种鸭坦布苏病毒弱毒疫苗株及其应用 |
EP3493839A1 (en) * | 2016-08-03 | 2019-06-12 | Takeda Vaccines, Inc. | Compositions and methods for stabilizing flaviviruses with improved formulations |
CN107281481A (zh) * | 2017-08-02 | 2017-10-24 | 华派生物工程集团有限公司 | 一种伪狂犬活疫苗耐热冻干保护剂、制备方法和冻干疫苗及制备方法 |
CN108815517A (zh) * | 2018-07-13 | 2018-11-16 | 广东永顺生物制药股份有限公司 | 一种鸭瘟活疫苗及其制备方法 |
CN108992674A (zh) * | 2018-07-13 | 2018-12-14 | 广东永顺生物制药股份有限公司 | 一种耐热保护剂及其应用 |
Non-Patent Citations (3)
Title |
---|
李永洲;戴波涛;赵刚;: "兽用疫苗耐热保护剂的种类及作用机理", 现代畜牧兽医, no. 04 * |
杨泽林, 吴宣, 饶德安, 齐雪峰: "耐热冻干保护剂及其在兽用冻干活疫苗中的应用", 四川畜牧兽医, no. 12 * |
陈果亮: "新城疫(ND-C30)活疫苗耐热保护剂的筛选", 《扬州大学硕士学位论文》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116440282A (zh) * | 2023-05-09 | 2023-07-18 | 中海生物制药(泰州)有限公司 | 一种鸡传染性支气管炎活疫苗冻干保护剂及其制备方法 |
CN116440282B (zh) * | 2023-05-09 | 2023-10-20 | 中海生物制药(泰州)有限公司 | 一种鸡传染性支气管炎活疫苗冻干保护剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113730592B (zh) | 2023-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102166362B (zh) | 猪繁殖与呼吸综合征活疫苗耐热冻干保护剂及制备方法 | |
CN110354259B (zh) | 一种鸭呼肠孤病毒灭活疫苗的制备方法 | |
CN104946600B (zh) | 一种h9亚型禽流感病毒株 | |
CN111000993B (zh) | 一种鸭病毒性肝炎、鸭呼肠孤病毒病二联灭活疫苗及其制备方法 | |
CN113491767A (zh) | 鸭圆环病毒病、新型鸭呼肠弧病毒病、鸭病毒性肝炎三联灭活疫苗及其制备方法 | |
CN101690808A (zh) | 猪瘟、伪狂犬病二联活疫苗的制备方法及其制品 | |
CN104258386B (zh) | 一种水貂病毒性肠炎灭活疫苗-犬瘟热活疫苗组合 | |
CN103861098B (zh) | 一种猪流行性腹泻和大肠埃希氏菌二联疫苗 | |
CN113730592A (zh) | 一种鸭坦布苏病毒病活疫苗冻干保护剂及制备方法和应用 | |
CN102727883B (zh) | 猪繁殖与呼吸综合征与猪瘟二联疫苗及其用途 | |
CN108465107B (zh) | 一种鸭2型腺病毒和番鸭细小病毒病二联灭活疫苗 | |
CN115581772A (zh) | 一种疫苗冻干耐热保护剂及其制备方法和应用 | |
CN105920596B (zh) | 一种番鸭细小病毒病、小鹅瘟二联疫苗 | |
CN110404063B (zh) | 采用非免鸡蛋制备鸡传染性支气管炎病毒抗原的方法 | |
CN109055320B (zh) | 一株传染性支气管炎病毒分离株及在疫苗制备中的应用 | |
CN112094339A (zh) | 一种猪圆环病毒2型阳性血清及其制备方法 | |
CN106512017A (zh) | 用于猪支原体肺炎活疫苗耐热保护剂及其制备方法和应用 | |
CN108300703B (zh) | 鹿源牛病毒性腹泻灭活疫苗及其制备方法 | |
CN105582535A (zh) | 猪瘟、伪狂犬病二联活疫苗的制备方法及其制品 | |
CN112618706B (zh) | 沙门氏菌、鸭疫里默氏杆菌、大肠埃希氏杆菌病三联疫苗 | |
CN109022372B (zh) | 一种猪流行性腹泻病毒的培养方法 | |
CN109280648B (zh) | 一种制备水貂细小病毒性肠炎抗原蛋白复合物的方法、抗原蛋白复合物及其应用 | |
CN106511990A (zh) | 一种兽用冻干布氏菌病活疫苗的浓缩工艺及制备工艺 | |
CN107982532B (zh) | 一种鸭甲肝病毒抗原抗体复合物疫苗及其制备方法 | |
CN116115766B (zh) | 一种活疫苗耐热冻干保护剂及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Bin Inventor after: Lian Wei Inventor after: Wang Shi Inventor after: Song Songlin Inventor after: Yang Zhongru Inventor after: Yu Zhigang Inventor after: Zhang Zeyue Inventor after: Jing Likun Inventor before: Liu Bin Inventor before: Yang Zhongru Inventor before: Yu Zhigang Inventor before: Zhang Zeyue Inventor before: Jing Likun |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |